Reddy Sriya A, Rivera Vargas Natalie, Varshney Aarushi, Karasik Olga
Internal Medicine, University of Central Florida (UCF) Hospital Corporation of America (HCA) Graduate Medical Education (GME) Consortium, Orlando, USA.
Internal Medicine, University of Central Florida College of Medicine, Orlando, USA.
Cureus. 2024 Jul 10;16(7):e64267. doi: 10.7759/cureus.64267. eCollection 2024 Jul.
SARS-COVID-19 is known to manifest with a wide variety of symptoms, most of which are respiratory. Myalgias are a common symptom of COVID-19, but cases of severe virus-induced inflammatory muscle injury leading to rhabdomyolysis and polymyositis have also been reported. Here, we present and discuss a case of a 56-year-old woman who presented with an initial presentation of COVID-19 infection with inflammatory polymyositis leading to rhabdomyolysis. The patient was first treated for rhabdomyolysis with aggressive fluid resuscitation with intravenous normal saline without improvement in symptoms. She was then started on high-dose intravenous methylprednisolone for presumed immune-mediated polymyositis. An MRI of the bilateral lower extremities and a biopsy of the left thigh confirmed inflammatory myositis. After the initiation of steroids, liver function tests and creatinine kinase levels trended down, and symptoms improved. The patient was discharged with a prednisone taper and completely recovered at a follow-up six months later. Post-COVID severe musculoskeletal involvement, including polymyositis or rhabdomyolysis, is rare, with only a few other cases published so far. Viral myositis, supported by myopathological evidence, should be considered carefully in patients with a recent COVID-19 infection after ruling out more common causes of myositis. Some proposed mechanisms include direct infection of the muscle or an environmental event triggering autoimmunity. Treatment generally involves corticosteroids that are gradually tapered.
已知严重急性呼吸综合征冠状病毒2(SARS-CoV-19)会表现出多种多样的症状,其中大多数为呼吸道症状。肌痛是冠状病毒病(COVID-19)的常见症状,但也有报告称出现了严重的病毒诱导性炎症性肌肉损伤,导致横纹肌溶解和多发性肌炎。在此,我们报告并讨论一例56岁女性病例,该患者最初表现为COVID-19感染并伴有炎症性多发性肌炎,进而导致横纹肌溶解。患者最初因横纹肌溶解接受积极的静脉输注生理盐水液体复苏治疗,但症状并无改善。随后,鉴于推测为免疫介导的多发性肌炎,开始对其使用大剂量静脉注射甲泼尼龙治疗。双侧下肢的磁共振成像(MRI)以及左大腿活检证实为炎症性肌炎。开始使用类固醇后,肝功能检查和肌酸激酶水平呈下降趋势,症状有所改善。患者出院时逐渐减少泼尼松用量,6个月后的随访显示已完全康复。COVID-19感染后出现严重的肌肉骨骼受累,包括多发性肌炎或横纹肌溶解,较为罕见,迄今为止仅有少数其他病例报道。在排除更常见的肌炎病因后,对于近期感染COVID-19的患者,应仔细考虑有肌病理证据支持的病毒性肌炎。一些提出的机制包括肌肉的直接感染或触发自身免疫的环境因素。治疗通常包括逐渐减量的皮质类固醇。